U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H13NO3S2
Molecular Weight 319.399
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of EPALRESTAT

SMILES

CC(=C/C1=CC=CC=C1)\C=C2/SC(=S)N(CC(O)=O)C2=O

InChI

InChIKey=CHNUOJQWGUIOLD-NFZZJPOKSA-N
InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-

HIDE SMILES / InChI
Molecular Formula C15H13NO3S2
Molecular Weight 319.399
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 2
Optical Activity NONE

Description

Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Aldose reductase
44
Target ID: P15121
Gene ID: 231.0
Gene Symbol: AKR1B1
Target Organism: Homo sapiens (Human)
Inhibitor
8297
 0.28 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
KINEDAK

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
1998 Jun
Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy.
2001 Jun
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
2011 Aug 15
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Patents

JP2001163805A
2
JP2002536332A
38
JP2004051520A
2
JP2004210702A
2
JP2004210703A
2
JP2004210766A
2
JP2004210775A
2
JP2005139085A
3
JP2005139086A
3
JP2005298424A
2
JP2006104064A
2
JP2006111601A
2
JP2006282526A
2
JP2006528156A
10
JP2007099680A
2
JP2007505083A
6
JP2007505085A
6
JP2009029717A
2
JP2011507800A
48
JP5294046B2
2

Sample Use Guides

In Vivo Use Guide
50 mg, 3 times/day
Route of Administration: Oral
In Vitro Use Guide
Human umbilical vein endothelial cells were cultured for 48 h in glucose-rich (27.8 mM) medium. The increased neutrophil-endothelial cell adhesion and surface expression of intercellular adhesion molecule-1 (ICAM-1), P-selectin, and E-selectin on endothelial cells was inhibited by 10 microM of epalrestat.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:30:20 GMT 2023
Edited
by admin
on Fri Dec 15 16:30:20 GMT 2023
Record UNII
424DV0807X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EPALRESTAT
INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
ALDONIL
Brand Name English
5-((Z,E)-.BETA.-METHYLCINNAMYLIDENE)-4-OXO-2-THIOXO-3-THIAZOLIDINEACETIC ACID
Systematic Name English
KINEDAK
Brand Name English
EPALRESTAT [JAN]
Common Name English
epalrestat [INN]
Common Name English
Epalrestat [WHO-DD]
Common Name English
EPALRESTAT [MART.]
Common Name English
EPALRESTAT [MI]
Common Name English
ALDORIN
Brand Name English
TANGLIN
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C72880
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
FDA ORPHAN DRUG 735820
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
Code System Code Type Description
MERCK INDEX
m4930
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY Merck Index
PUBCHEM
1549120
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
NCI_THESAURUS
C72762
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
FDA UNII
424DV0807X
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
MESH
C038131
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID1046479
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
ChEMBL
CHEMBL56337
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
DRUG BANK
DB15293
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
CAS
82159-09-9
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
CHEBI
31539
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
INN
5896
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
SMS_ID
100000080262
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
EVMPD
SUB06557MIG
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
WIKIPEDIA
EPALRESTAT
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
DRUG CENTRAL
1021
Created by admin on Fri Dec 15 16:30:20 GMT 2023 , Edited by admin on Fri Dec 15 16:30:20 GMT 2023
PRIMARY
Related Record Type Details
Structure of DIEPALRESTAT CHOLINE
SALT/SOLVATE -> PARENT
ALDOSE REDUCTASE
TARGET -> INHIBITOR
Related Record Type Details
Structure of EPALRESTAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966